Characteristics of the patients, CB units, and of the transplant procedure
| Covariates . | n (%) . | Range . | Missing, n (%) . |
|---|---|---|---|
| Follow-up time (patient alive at last news), median, y | 6 | 0.26-16.2 | |
| Recipient sex | |||
| Male | 229 (60) | ||
| Female | 154 (40) | ||
| Diagnosis | |||
| Acute lymphoblastic leukemia | 102 (26.5) | ||
| Acute myeloid leukemia | 232 (61) | ||
| Acute leukemia (unknown type) | 10 (2.5) | ||
| MDS | 39 (10) | ||
| Secondary leukemia | 27 (8) | ||
| No | 270 (78.5) | ||
| Yes | 47 (13.5) | ||
| Cytogenetics | 75 (20) | ||
| Good risk | 28 (7) | ||
| Intermediate risk | 195 (51) | ||
| Poor risk | 85 (22) | ||
| Disease status at transplant | 14 (4) | ||
| CR1 | 212 (55) | ||
| CR2 | 112 (29) | ||
| CR >2 or active disease | 45 (12) | ||
| Recipient age at transplant, y | |||
| Median | 41 | 5-73 | |
| <18 | 46 (12) | ||
| >18 | 337 (88) | ||
| <40 | 177 (46) | ||
| >40 | 206 (54) | ||
| Recipient body weight at transplant, kg | 7 (1.5) | ||
| <70 | 179 (47) | ||
| >70 | 197 (51.5) | ||
| Year of transplant | |||
| <2012 | 185 (48) | ||
| >2012 | 198 (52) | ||
| Time from diagnosis to transplant, mo | 8 (2) | ||
| <12 | 232 (61) | ||
| >12 | 143 (37) | ||
| Recipient CMV serology | 5 (2) | ||
| Negative | 170 (44) | ||
| Positive | 208 (54) | ||
| ABO matching with the recipient∗ | 55 (14) | ||
| ABO compatible | 60 (16) | ||
| Minor ABO incompatibility | 81 (21) | ||
| Major ABO incompatibility | 187 (49) | ||
| HLA mismatches including HLA-C† | |||
| 0 or 1 | 2 + 17 (5) | ||
| 2 | 110 (29) | ||
| 3 | 172 (45) | ||
| 4 or 5 | 78 + 4 (21) | ||
| Conditioning regimen intensity | 8 (2) | ||
| Myeloablative | 163 (42.5) | ||
| CY FLU + TBI | 126 | ||
| Other | 37 | ||
| Reduced intensity | 212 (55.5) | ||
| CY FLU + low-dose TBI | 183 | ||
| Others | 29 | ||
| TBI | 11 (3) | ||
| No | 34 (9) | ||
| Yes | 338 (88) | ||
| GVHD prophylaxis | 7 (2) | ||
| Cyclosporine and mycophenolate mofetil | 322 (84) | ||
| Other prophylaxis | 54 (14) | ||
| TNC dose at collection‡ | 49 (13) | ||
| Median, ×107 | 5.37 | 1.44-34.35 | |
| CD34+ cell dose at collection‡ | 57 (15) | ||
| Median, ×105 | 2.20 | 0.16-10.25 | |
| PT-LU HLA shared mismatch against WU (any HLA-A, -B, -C, or -DRB1 locus) | |||
| No | 192 (50) | ||
| Yes | 191 (50) | ||
| PT-LU HLA class-1 shared mismatch against WU (HLA-A, -B, and -C loci) | |||
| No | 223 (58) | ||
| Yes | 160 (42) | ||
| PT-LU HLA-A shared mismatch against WU | |||
| No | 315 (82) | ||
| Yes | 68 (18) | ||
| PT-LU HLA-B shared mismatch against WU | |||
| No | 325 (85) | ||
| Yes | 58 (15) | ||
| PT-LU HLA-C shared mismatch against WU | |||
| No | 306 (80) | ||
| Yes | 77 (20) | ||
| PT-LU HLA-DRB1 shared mismatch against WU | 1 (<1) | ||
| No | 335 (87.5) | ||
| Yes | 47 (12.5) |
| Covariates . | n (%) . | Range . | Missing, n (%) . |
|---|---|---|---|
| Follow-up time (patient alive at last news), median, y | 6 | 0.26-16.2 | |
| Recipient sex | |||
| Male | 229 (60) | ||
| Female | 154 (40) | ||
| Diagnosis | |||
| Acute lymphoblastic leukemia | 102 (26.5) | ||
| Acute myeloid leukemia | 232 (61) | ||
| Acute leukemia (unknown type) | 10 (2.5) | ||
| MDS | 39 (10) | ||
| Secondary leukemia | 27 (8) | ||
| No | 270 (78.5) | ||
| Yes | 47 (13.5) | ||
| Cytogenetics | 75 (20) | ||
| Good risk | 28 (7) | ||
| Intermediate risk | 195 (51) | ||
| Poor risk | 85 (22) | ||
| Disease status at transplant | 14 (4) | ||
| CR1 | 212 (55) | ||
| CR2 | 112 (29) | ||
| CR >2 or active disease | 45 (12) | ||
| Recipient age at transplant, y | |||
| Median | 41 | 5-73 | |
| <18 | 46 (12) | ||
| >18 | 337 (88) | ||
| <40 | 177 (46) | ||
| >40 | 206 (54) | ||
| Recipient body weight at transplant, kg | 7 (1.5) | ||
| <70 | 179 (47) | ||
| >70 | 197 (51.5) | ||
| Year of transplant | |||
| <2012 | 185 (48) | ||
| >2012 | 198 (52) | ||
| Time from diagnosis to transplant, mo | 8 (2) | ||
| <12 | 232 (61) | ||
| >12 | 143 (37) | ||
| Recipient CMV serology | 5 (2) | ||
| Negative | 170 (44) | ||
| Positive | 208 (54) | ||
| ABO matching with the recipient∗ | 55 (14) | ||
| ABO compatible | 60 (16) | ||
| Minor ABO incompatibility | 81 (21) | ||
| Major ABO incompatibility | 187 (49) | ||
| HLA mismatches including HLA-C† | |||
| 0 or 1 | 2 + 17 (5) | ||
| 2 | 110 (29) | ||
| 3 | 172 (45) | ||
| 4 or 5 | 78 + 4 (21) | ||
| Conditioning regimen intensity | 8 (2) | ||
| Myeloablative | 163 (42.5) | ||
| CY FLU + TBI | 126 | ||
| Other | 37 | ||
| Reduced intensity | 212 (55.5) | ||
| CY FLU + low-dose TBI | 183 | ||
| Others | 29 | ||
| TBI | 11 (3) | ||
| No | 34 (9) | ||
| Yes | 338 (88) | ||
| GVHD prophylaxis | 7 (2) | ||
| Cyclosporine and mycophenolate mofetil | 322 (84) | ||
| Other prophylaxis | 54 (14) | ||
| TNC dose at collection‡ | 49 (13) | ||
| Median, ×107 | 5.37 | 1.44-34.35 | |
| CD34+ cell dose at collection‡ | 57 (15) | ||
| Median, ×105 | 2.20 | 0.16-10.25 | |
| PT-LU HLA shared mismatch against WU (any HLA-A, -B, -C, or -DRB1 locus) | |||
| No | 192 (50) | ||
| Yes | 191 (50) | ||
| PT-LU HLA class-1 shared mismatch against WU (HLA-A, -B, and -C loci) | |||
| No | 223 (58) | ||
| Yes | 160 (42) | ||
| PT-LU HLA-A shared mismatch against WU | |||
| No | 315 (82) | ||
| Yes | 68 (18) | ||
| PT-LU HLA-B shared mismatch against WU | |||
| No | 325 (85) | ||
| Yes | 58 (15) | ||
| PT-LU HLA-C shared mismatch against WU | |||
| No | 306 (80) | ||
| Yes | 77 (20) | ||
| PT-LU HLA-DRB1 shared mismatch against WU | 1 (<1) | ||
| No | 335 (87.5) | ||
| Yes | 47 (12.5) |
CMV, cytomegalovirus; CR1, first complete remission; CR2, second CR; CY, cyclophosphamide; FLU, fludarabine; TBI, total body irradiation; TNC, total nucleated cell.
Considering the least compatible CB unit.
Low-resolution typing for HLA-A and HLA-B and HLA-C; high-resolution typing for HLA-DRB1, considering the least HLA-compatible CB unit.
Considering both CB units (total dose).